Literature DB >> 7523061

Vascular versus myocardial effects of calcium antagonists.

W C Little1, C P Cheng.   

Abstract

As vascular smooth muscle tone and myocardial contractility both depend on calcium entry, the calcium antagonists are not only potent arterial vasodilators, but may also have important negative inotropic effects. For example, verapamil is nearly equipotent in reducing vascular smooth muscle tone and myocardial contraction in isolated tissue preparations. In contrast, felodipine has high vascular selectivity in such preparations, and drug concentrations required to depress myocardial contraction are more than 100 times greater than those required to relax vascular smooth muscle. In the isolated, isovolumetrically contracting canine left ventricle, clinically relevant concentrations of felodipine (14 nmol/L) produce coronary vasodilation and a mild positive inotropic response. Using left ventricular (LV) pressure-volume analysis, we evaluated a similar dose of felodipine (plasma drug concentration 16 nmol/L) in conscious dogs. Felodipine produced a 25mm Hg fall in arterial pressure and a 10% reduction in peripheral vascular resistance. There was no negative inotropic effect. Instead, myocardial contractile performance was slightly but significantly enhanced. These results were not altered by adrenergic blockade. Further studies in our laboratory showed that doses of amlodipine and nifedipine producing arterial vasodilation of a magnitude similar to that produced by felodipine had negative inotropic effects in the conscious dog. Only felodipine enhanced the rate of LV relaxation and the rate of early diastolic filling. Thus, felodipine was significantly more vasoselective than amlodipine and nifedipine. The direct inotropic effects of calcium antagonists are difficult to evaluate in clinical studies because of the load-dependence of most conventional measures of LV performance. However, no negative inotropic effects are clinically relevant doses of felodipine have been identified.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523061     DOI: 10.2165/00003495-199400474-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  28 in total

1.  Second generation calcium channel blockers in the treatment of chronic heart failure: are they any better than their predecessors?

Authors:  M Packer
Journal:  J Am Coll Cardiol       Date:  1989-11-01       Impact factor: 24.094

2.  Haemodynamic effects of short and long term administration of felodipine in spontaneously hypertensive rats.

Authors:  M Nordlander
Journal:  Drugs       Date:  1985       Impact factor: 9.546

3.  A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure.

Authors:  U Elkayam; J Amin; A Mehra; J Vasquez; L Weber; S H Rahimtoola
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

4.  Ca-agonists: a new class of inotropic drugs.

Authors:  M Bechem; R Gross; S Hebisch; M Schramm
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 5.  Hemodynamic effects of felodipine in hypertension: a review.

Authors:  P Lund-Johansen
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

6.  Long-term clinical, hemodynamic, angiographic, and neurohumoral responses to vasodilation with felodipine in patients with chronic congestive heart failure.

Authors:  E Kassis; O Amtorp
Journal:  J Cardiovasc Pharmacol       Date:  1990-03       Impact factor: 3.105

7.  Reflex chronotropic and inotropic effects of calcium channel-blocking agents in conscious dogs. Diltiazem, verapamil, and nifedipine compared.

Authors:  H Nakaya; A Schwartz; R W Millard
Journal:  Circ Res       Date:  1983-03       Impact factor: 17.367

8.  Vascular selectivity of felodipine.

Authors:  B Ljung
Journal:  Drugs       Date:  1985       Impact factor: 9.546

9.  The effects of felodipine on left ventricular function in beta-blocked patients.

Authors:  A J Drake-Holland; S Pugh; C Mills; M I Noble
Journal:  Drugs       Date:  1987       Impact factor: 9.546

10.  Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease.

Authors:  W Culling; M S Ruttley; D J Sheridan
Journal:  Br Heart J       Date:  1984-10
View more
  6 in total

Review 1.  New lines in therapy of Raynaud's phenomenon.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

2.  Long-acting calcium channel antagonist pranidipine prevents ventricular remodeling after myocardial infarction in rats.

Authors:  K Takeuchi; T Omura; M Yoshiyama; K Yoshida; R Otsuka; Y Shimada; K Ujino; J Yoshikawa
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

3.  Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex.

Authors:  R D Cohn; M Durbeej; S A Moore; R Coral-Vazquez; S Prouty; K P Campbell
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 4.  Diastolic heart failure in the elderly.

Authors:  Dalane W Kitzman
Journal:  Heart Fail Rev       Date:  2002-01       Impact factor: 4.214

Review 5.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

6.  Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca2+ signalling.

Authors:  Serena Stadler; Chi Huu Nguyen; Helga Schachner; Daniela Milovanovic; Silvio Holzner; Stefan Brenner; Julia Eichsteininger; Mira Stadler; Daniel Senfter; Liselotte Krenn; Wolfgang M Schmidt; Nicole Huttary; Sigurd Krieger; Oskar Koperek; Zsuzsanna Bago-Horvath; Konstantin Alexander Brendel; Brigitte Marian; Oliver de Wever; Robert M Mader; Benedikt Giessrigl; Walter Jäger; Helmut Dolznig; Georg Krupitza
Journal:  Cell Mol Life Sci       Date:  2016-12-24       Impact factor: 9.261

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.